Diffusion Pharmaceuticals Inc. DFFN
We take great care to ensure that the data presented and summarized in this overview for Diffusion Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in DFFN
Top Purchases
Top Sells
About DFFN
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Insider Transactions at DFFN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 27
2024
|
William Robert Elder CFO & GC |
BUY
Open market or private purchase
|
Direct |
1,000
+44.11%
|
$18,000
$18.16 P/Share
|
|
Feb 26
2024
|
Joshua S Boger Director |
SELL
Open market or private sale
|
Indirect |
36
-0.0%
|
-
|
|
Feb 26
2024
|
Joshua S Boger Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
495,995
+37.11%
|
-
|
|
Nov 09
2023
|
John J Alam CEO & President |
SELL
Bona fide gift
|
Direct |
12,500
-1.68%
|
-
|
|
Nov 09
2023
|
Sylvie Gregoire Director |
SELL
Bona fide gift
|
Direct |
10,000
-1.35%
|
-
|
|
Aug 31
2023
|
Jane H Hollingsworth Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
45
-4.77%
|
-
|
|
Aug 31
2023
|
Jane H Hollingsworth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
122
+11.46%
|
-
|
|
Jun 30
2023
|
Diana M Lanchoney Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
85
-22.43%
|
-
|
|
Jun 30
2023
|
Diana M Lanchoney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
232
+37.97%
|
-
|
|
May 31
2023
|
Jane H Hollingsworth Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
68
-5.23%
|
-
|
|
May 31
2023
|
Jane H Hollingsworth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
183
+12.35%
|
-
|
|
Mar 31
2023
|
Diana M Lanchoney Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
85
-36.64%
|
-
|
|
Mar 31
2023
|
Diana M Lanchoney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
232
+50.0%
|
-
|
|
Feb 28
2023
|
Jane H Hollingsworth Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
68
-5.74%
|
-
|
|
Feb 28
2023
|
Jane H Hollingsworth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
183
+13.39%
|
-
|
|
Jan 31
2023
|
Robert Joseph Cobuzzi Jr. Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
121
-6.97%
|
-
|
|
Jan 31
2023
|
Robert Joseph Cobuzzi Jr. Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
327
+15.84%
|
-
|
|
Nov 30
2022
|
Jane H Hollingsworth Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
68
-6.36%
|
-
|
|
Nov 30
2022
|
Jane H Hollingsworth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
183
+14.62%
|
-
|
|
Oct 31
2022
|
Robert Joseph Cobuzzi Jr. Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
121
-7.9%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 1K shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 496K shares |
| Open market or private sale | 36 shares |
|---|